Clinical Trial Update: Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease [Phase 3]

View source ↗

Summary

Phase 3 extension study update on Replagal in adults with Fabry disease assessing safety and clinical outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Replagal (agalsidase alfa)

Snippet

Sponsor: Shire | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-08-22